Soleno Therapeutics, Inc.
NASDAQ:SLNO
76.78 (USD) • At close May 9, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1,553.002 | 1.451 | 0.388 | 0 | 3 | 0 |
| Cost of Revenue
| 0 | 1.958 | 2.21 | 2.207 | 2.194 | 2.297 | 1.919 | 1.611 | 1.509 | 0.353 | 0 | 0 | 0 |
| Gross Profit
| 0 | -1.958 | -2.21 | -2.207 | -2.194 | -2.297 | -1.919 | -1,554.613 | -0.059 | 0.035 | 0 | 3 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.001 | -0.04 | 0.09 | 0 | 1 | 0 |
| Reseach & Development Expenses
| 78.568 | 25.189 | 15.265 | 21.453 | 23.191 | 16.267 | 7.178 | 3.069 | 5.185 | 4.536 | 2.242 | 2.38 | 2.47 |
| General & Administrative Expenses
| 105.861 | 13.481 | 9.844 | 10.806 | 8.758 | 6.93 | 6.556 | 6.585 | 6.736 | 6.141 | 2.665 | 1.467 | 1.127 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.026 | 1.631 | 1.737 | 0.252 | 0 | 0 |
| SG&A
| 105.861 | 13.481 | 9.844 | 10.806 | 8.758 | 6.93 | 6.556 | 6.61 | 8.367 | 7.878 | 2.918 | 1.467 | 1.127 |
| Other Expenses
| 0 | 2.714 | 0 | 0 | 4.34 | 0.289 | 0.006 | -0.586 | -0.101 | -0.184 | -4.585 | -0.002 | -0.022 |
| Operating Expenses
| 187.671 | 41.384 | 25.109 | 32.259 | 31.949 | 23.197 | 13.734 | 9.679 | 13.552 | 12.195 | 5.16 | 3.847 | 3.597 |
| Operating Income
| -184.429 | -41.384 | -24.397 | -31.528 | -36.289 | -23.486 | -14.301 | -12.171 | -13.61 | -12.16 | -5.16 | -0.847 | -3.597 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.008 | -9.381 | -31.376 | 0 | -0.282 | 0 |
| Total Other Income Expenses Net
| 8.579 | 2.396 | 0.33 | 0.618 | 11.65 | -7.288 | 2.46 | -1.271 | 1.586 | -3.749 | -8.078 | -2.86 | -2.885 |
| Income Before Tax
| -175.85 | -38.988 | -24.067 | -30.91 | -24.639 | -30.774 | -11.841 | -13.724 | -12.044 | -15.909 | -13.875 | -3.707 | -6.482 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.009 | -8.301 | -41.048 | 0 | -1.236 | 0 |
| Income Tax Expense
| 0 | 0 | -3.748 | -1.349 | -9.264 | 5.141 | 2.522 | -1.65 | 0.022 | -0.184 | -0.455 | 2.858 | 2.843 |
| Net Income
| -175.85 | -38.988 | -20.319 | -29.561 | -15.375 | -35.915 | -13.335 | -15.667 | -12.065 | -15.909 | -13.875 | -3.707 | -6.482 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | -8.316 | -41.048 | 0 | -1.236 | 0 |
| EPS
| -4.38 | -2.36 | -2.42 | -5.56 | -3.68 | -15.78 | -9.54 | -26.18 | -58.35 | -126.58 | -819.38 | -198.45 | -346.98 |
| EPS Diluted
| -4.38 | -2.36 | -2.42 | -5.56 | -3.68 | -15.78 | -9.54 | -26.18 | -58.35 | -126.58 | -819.38 | -198.45 | -346.98 |
| EBITDA
| -173.632 | -37.03 | -21.857 | -28.703 | -29.995 | -28.477 | -9.922 | -8.068 | -6.718 | -15.8 | -5.131 | -0.805 | -3.573 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.005 | -4.631 | -40.769 | 0 | -0.268 | 0 |